Raymond James Financial
NRXP icon

Raymond James Financial’s NRX Pharmaceuticals NRXP Stock Holding History

Raymond James Financial’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,571
Closed -$8.38K – 6130
2025
Q2 		$8.38K Buy
+2,571
New +$6.44K ﹤0.01% 5991

Other funds holding NRXP

AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial's NRXP Position: Q3 2025 in Review

Raymond James Financial sold out of NRX Pharmaceuticals (NRXP) in Q3 2025, closing a stake of 2,571 shares — an estimated $8.38K sold.

Raymond James Financial first reported a position in NRXP in Q2 2025 and held it in 1 quarter. The position peaked at $8.38K in Q2 2025. 24 funds tracked by Wall St. Rank hold NRXP as of Q3 2025.

  • Raymond James Financial reported no remaining NRX Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 2,571 NRX Pharmaceuticals shares in Q3 2025, an estimated $8.38K.
  • Raymond James Financial first reported a position in NRX Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's NRX Pharmaceuticals position peaked at $8.38K in Q2 2025.
  • 24 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.